ScripThe pace of initial public offerings in the US predictably slowed during the summer, although whether the slowdown was caused by financial market conditions or vacation schedules remains to be seen. E
ScripIt is too early to say that biotech IPOs are back. But the showing in the first quarter of this year is cheering: more flotations got away since the first quarter of 2022, according to Evaluate Pharm
ScripLess than three years after Mallinckrodt plc filed for bankruptcy protection to reorganize its finances in a manner that would allow for repayment of its debts and payouts under opioid litigation se
ScripRaising venture capital or launching an initial public offering in 2023 is nowhere near as easy as it was in the record-breaking VC funding and IPO days of 2020 and 2021, after a rough 2022 when fundr